Company news

Aurinia Pharmaceuticals Inc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Aurinia Pharmaceuticals to Present at the SVB Leerink 10th Annual Global Healthcare Conference

February 17, 2021

Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021

February 16, 2021

FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis

January 21, 2021

Aurinia Pharmaceuticals to Present at Two Upcoming Virtual Healthcare Conferences

January 7, 2021

Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan

December 16, 2020

Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

December 14, 2020

Aurinia Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

December 1, 2020

Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 19, 2020

Aurinia Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference

November 11, 2020

Aurinia Reports Third Quarter 2020 Financial Results and Recent Operational Highlights

November 9, 2020

Aurinia Presents Integrated Time to Renal Response Data from the AURA-LV and AURORA Trials, along with Voclosporin Drug-Drug Interaction Data at ACR Convergence 2020

November 8, 2020

Aurinia Announces Outcome of AUDREY™ Clinical Trial in Dry Eye Syndrome

November 1, 2020

Aurinia Announces European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19

October 26, 2020

Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials at ASN Kidney Week 2020

October 21, 2020

Aurinia Pharmaceuticals Announces Launch of Lupus Nephritis Disease-State Awareness Initiative for Healthcare Professionals, TimeIsNephrons.com

October 13, 2020

Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 1, 2020

Aurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eye Syndrome

September 27, 2020

Aurinia Pharmaceuticals to Present at Three Upcoming Virtual Investor Conferences

September 9, 2020

Aurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights

August 10, 2020

Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

August 3, 2020

Aurinia Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 11, 2020

July 29, 2020

Aurinia Closes US$200 Million Public Offering of Common Shares

July 26, 2020

Aurinia Prices US$200 Million Public Offering of Common Shares

July 21, 2020

Aurinia Announces Public Offering of Common Shares

July 21, 2020

Aurinia Announces U.S. Food and Drug Administration Acceptance of the Filing of New Drug Application and Priority Review for Voclosporin for the Treatment of Lupus Nephritis

July 20, 2020

Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome

June 21, 2020

Aurinia Presents Additional AURORA Pivotal Trial Safety Data at the ERA-EDTA Virtual Congress 2020

June 8, 2020

Aurinia Presents AURORA Pivotal Trial Subgroup Analysis at the EULAR 2020 E-Congress

June 4, 2020

Aurinia Announces Results of Annual General Meeting

June 2, 2020

Aurinia Completes Submission of New Drug Application to the U.S. Food & Drug Administration for Voclosporin for the Treatment of Lupus Nephritis

May 25, 2020

Aurinia Pharmaceuticals to Present at 2020 RBC Capital Markets’ Virtual Global Healthcare Conference

May 14, 2020

Aurinia Reports First Quarter 2020 Financial Results and Recent Operational Highlights

May 13, 2020

Aurinia Pharmaceuticals to Release First Quarter 2020 Financial Results on May 14, 2020

May 6, 2020

Aurinia Appoints Joe Miller as Chief Financial Officer

April 26, 2020

Aurinia Appoints Industry Veteran Timothy P. Walbert to its Board of Directors

April 19, 2020

Aurinia Announces AURORA Phase 3 Clinical Data for Voclosporin in Lupus Nephritis to be Presented at National Kidney Foundation 2020 Spring Clinical Meetings

March 17, 2020

Aurinia Pharmaceuticals Establishes U.S. Commercial Operations Center in Rockville, Maryland

March 16, 2020

Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis

March 15, 2020

Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative

March 11, 2020

Aurinia Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights

March 4, 2020

Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team

February 24, 2020

Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares

December 11, 2019

Aurinia Prices US$166.7 Million Public Offering of Common Shares

December 8, 2019

Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis

December 3, 2019

Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlights

November 13, 2019

Aurinia Announces Updates to the Board of Directors

November 12, 2019

Aurinia Completes Voclosporin Drug-Drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil

November 6, 2019

Aurinia Pharmaceuticals to Release Third Quarter 2019 Financial Results on November 14, 2019

November 5, 2019

Aurinia Announces Initiation of Patient Dosing in Phase 2/3 AUDREY™ Clinical Trial for Dry Eye Syndrome

October 30, 2019

Aurinia Reports Last Patient Study Visit in Aurora Phase 3 Lupus Nephritis Study and Provides Update on ATM Facility

October 15, 2019

← Newer news releases · Older news releases →

Calls

The 5 newest of 17 calls. Every call is listed under its year.

Decks

The 5 newest of 7 decks. Every deck is listed under its year.